Literature DB >> 11966795

Surgical management of rhinophyma: report of eight patients treated with electrosection.

Jordi Rex1, Miquel Ribera, Isabel Bielsa, Cristina Paradelo, Carlos Ferrándiz.   

Abstract

BACKGROUND: Rhinophyma is the end stage of rosacea, affecting almost exclusively male patients, characterized by a progressive deformity in nasal shape. Depending on the extent of the deformity, rhinophyma may distort the appearance of those affected and patients may become psychosocially disabled.
OBJECTIVE: To present the results of electrosurgical technique of sequential delamination with a slightly damped current in rhinophyma.
METHODS: Eight healthy male patients affected by moderate to severe rhinophyma were recruited. A radiofrequency electrosurgical unit was used in the cut/coagulate mode at 40 W (3.8 MHz) to remove thin layers of tissue until the nose shape was re-created.
RESULTS: All patients achieved acceptable cosmetic results. Cutaneous reepithelialization was achieved at day 14 after surgery. Erythema subsided within 4-8 weeks and healing was complete with minimal scar formation by 8-10 weeks. None of the patients developed hypertrophic scarring and hypopigmentation was minimal.
CONCLUSION: Electrosection is as effective as laser treatments and less expensive. Although living in a laser era, electrosurgical remodeling of the nose is a good alternative for the treatment of rhinophyma.

Entities:  

Mesh:

Year:  2002        PMID: 11966795     DOI: 10.1046/j.1524-4725.2002.01209.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

1.  Safety and Efficacy of Bipolar Radiofrequency Ablation Device in Hemostasis during Thyroidectomy in Comparison with Ultrasonic Scalpel: A Comparative Study.

Authors:  Sadeq G Kadem; Majid H Alabbood
Journal:  Indian J Endocrinol Metab       Date:  2019 Jan-Feb

2.  Microdebrider-Assisted Rhinophyma Excision.

Authors:  Abdulaziz Abushaala; Marios Stavrakas; Hisham Khalil
Journal:  Case Rep Otolaryngol       Date:  2019-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.